Physicians Realty Trust (now HealthPeak) reported strong Q4 and full-year 2024 results, exceeding its original guidance. Management provided an optimistic 2025 outlook, driven by a healthy balance sheet, a robust development pipeline, and a focus on structured debt investments in life science. 2024 FFO per share of $1.81, beating original guidance by $0.05, and 2025 guidance of $1.81-$1.87.
Physicians Realty Trust (now HealthPeak) reported strong Q4 and full-year 2024 results, exceeding its original guidance. Management provided an optimistic 2025 outlook, driven by a healthy balance sheet, a robust development pipeline, and a focus on structured debt investments in life science. 2024 FFO per share of $1.81, beating original guidance by $0.05, and 2025 guidance of $1.81-$1.87.
Physicians Realty Trust (now HealthPeak) reported strong Q4 and full-year 2024 results, exceeding its original guidance. Management provided an optimistic 2025 outlook, driven by a healthy balance sheet, a robust development pipeline, and a focus on structured debt investments…
2024 FFO per share of $1.81, beating original guidance by $0.05, and 2025 guidance of $1.81-$1.87.
Plan to deploy $500 million in 2025, focusing on life science loans with purchase options (8%+ yields) and pre-leased outpatient medical developments.
Signed leases for over 50% of the $60 million NOI upside from development projects, but this won't hit earnings until late 2025, creating a tailwind for 2026.
Management is confident in its growth trajectory, citing strong 2024 results, a robust development pipeline, and a deleveraged balance sheet, positioning the company to go on the offensive in 2025.
Management is increasing capital allocation to on-balance-sheet investments, including $500 million in 2025 guidance, primarily for life science loans and outpatient medical development, with an expected weighted average yield of 8% plus. They also plan $600 million in development and redevelopment spend this year, which may be a slight earnings drag, but they see it as building for future growth.
Management is assertive and positive about their execution, growth trajectory, and the opportunity set, emphasizing balance sheet strength and platform advantages.
“With new deliveries declining by 75% this year, new starts at nearly zero, and many new entrants and lenders feeling distressed, We see this as a great time to put our platform and balance sheet to work.”
“The $75 million mortgage loan we announced yesterday is a good example of this targeted approach.”
“Our 2025 guidance excludes four pennies of FFO from signed but not yet occupied leases.”
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| Capex | FY2025 | $600M | $600M | INITIATED |
| EPS | FY2025 | $1.81–$1.87 | $1.84 | INITIATED |
| RevenueOUTPATIENT_MEDICAL_SAME_ | FY2025 | 2.5%–3.5% | 3% | INITIATED |
| RevenueLAB_SAME_STORE | FY2025 | 3%–4% | 3.5% | INITIATED |
| RevenueCCRC_SAME_STORE | FY2025 | 4%–8% | 6% | INITIATED |
McKesson is pre-leasing a new development adjacent to a Baylor Scott and White Hospital in Dallas, signaling its expansion and commitment to the outpatient medical space.
“originated a $36 million development loan with purchase option on a development that's 100% pre-leased to McKesson”
… the street from our existing 700,000 square foot campus in Torrey Pines, the premier sub market in San Diego. Our loan to cost is 60% with an 8% interest rate plus purchase option. In our outpatient medical business, our health system driven strategy generates sustainable internal and external growth. Our capabilities and relationships were built over the past two decades and continue to bring us proprietary opportunities. In the fourth quarter, we originated a $36 million development loan with purchase option on a development that's 100% pre-leased to McKesson and adjacent to a Baylor Scott and White Hospital in Dallas. Our current pipeline of similar highly pre-leased and accreted development projects exceeds $300 million. I'd like to make a few comments about our senior housing CCRC portfolio. Over the past several years, we've executed a strategy to structure our entry fees so that less than 20% of those fees are refundable to the resident. This is a huge contrast from the typical CCRC where the entry fee is more than 80% refundable to the resident. This strategy around refundability allowed us to keep the entry fee low so that we could target a wider audience. The result …